Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | CASP7 | P55210 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17274923 | 0.87 | THRB (0.42) | MAPTTDP1CASP1CASP7USP2 | |
| SCHEMBL17274871 | 0.84 | POLB (0.56) | MAPTTDP1L3MBTL1CASP1CASP7 | |
| SCHEMBL18655576 | 0.84 | MAPT (0.57) | MAPTTDP1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17274758 | 0.84 | MAOA (0.54) | MAPTTDP1CYP1A2CYP3A4L3MBTL1 | |
| SCHEMBL17274925 | 0.79 | MAPT (0.54) | MAPTTDP1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1921824 | 0.74 | PSEN1 (0.57) | MAPTLMNAMAPK1KDM4EPLK1 | |
| SCHEMBL18655578 | 0.70 | MAPT (0.53) | MAPTTDP1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20340615 | 0.69 | CHUK (0.44) | MAPTL3MBTL1TSHRMAPK1KDM4E | |
| SCHEMBL18655577 | 0.69 | MAPT (0.67) | MAPTTDP1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1921889 | 0.68 | ALDH1A1 (0.60) | MAPTTDP1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | claimed |
| EP-3145507-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | Musc Foundation for Research Development (US) | 2017-03-29 | — | — | EP | claimed |
| WO-2015179218-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-11-26 | — | — | WO | claimed |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| WO-2015179218-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | AZI2, DNMT1, TET3 | MAPT 3584/4885TDP1 1327/4885CYP1A2 31/4885 |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | AZI2, DNMT1, TET3 | MAPT 3584/4885TDP1 1327/4885CYP1A2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.